Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level

CONTEXT: In an open-label, randomized, controlled, phase 3 trial in 61 children aged 1 to 12 years with X-linked hypophosphatemia (XLH), burosumab improved rickets vs continuing conventional therapy with active vitamin D and phosphate. OBJECTIVE: We conducted an analysis to determine whether skeleta...

Descripción completa

Detalles Bibliográficos
Autores principales: Imel, Erik A, Glorieux, Francis H, Whyte, Michael P, Portale, Anthony A, Munns, Craig F, Nilsson, Ola, Simmons, Jill H, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Pitukcheewanont, Pisit, Sochett, Etienne, Högler, Wolfgang, Muroya, Koji, Tanaka, Hiroyuki, Gottesman, Gary S, Biggin, Andrew, Perwad, Farzana, Chen, Angel, Roberts, Mary Scott, Ward, Leanne M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583998/
https://www.ncbi.nlm.nih.gov/pubmed/37084401
http://dx.doi.org/10.1210/clinem/dgad230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583998/
https://www.ncbi.nlm.nih.gov/pubmed/37084401
http://dx.doi.org/10.1210/clinem/dgad230

Ejemplares similares